Literature DB >> 22510583

Resistance, not tachyphylaxis or tolerance.

Olli Arjamaa, Heikki Minn.   

Abstract

Mesh:

Substances:

Year:  2012        PMID: 22510583     DOI: 10.1136/bjophthalmol-2012-301823

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  5 in total

Review 1.  Diabetic macular oedema: pathophysiology, management challenges and treatment resistance.

Authors:  Bobak Bahrami; Meidong Zhu; Thomas Hong; Andrew Chang
Journal:  Diabetologia       Date:  2016-05-14       Impact factor: 10.122

2.  Genetic Variants of Complement Factor H Y402H (rs1061170), C2 R102G (rs2230199), and C3 E318D (rs9332739) and Response to Intravitreal Anti-VEGF Treatment in Patients with Exudative Age-Related Macular Degeneration.

Authors:  Agnieszka Kubicka-Trząska; Katarzyna Żuber-Łaskawiec; Sylwia Dziedzina; Marek Sanak; Bożena Romanowska-Dixon; Izabella Karska-Basta
Journal:  Medicina (Kaunas)       Date:  2022-05-13       Impact factor: 2.948

Review 3.  Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review.

Authors:  Shiqi Yang; Jingke Zhao; Xiaodong Sun
Journal:  Drug Des Devel Ther       Date:  2016-06-02       Impact factor: 4.162

4.  Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance.

Authors:  Ali Dirani; Irmela Mantel
Journal:  Clin Ophthalmol       Date:  2018-03-28

5.  Prospective PED-study of intravitreal aflibercept for refractory vascularized pigment epithelium detachment due to age-related macular degeneration: morphologic characteristics of non-responders in optical coherence tomography.

Authors:  C R Clemens; F Alten; J Termühlen; N Mihailovic; F Rosenberger; P Heiduschka; N Eter
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-04-18       Impact factor: 3.117

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.